JamesThrasherMDFellow American College of Endocrinology

Clinical Trials

• Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) Start of enrollment: 2010 Jun 01

  Completed

  Phase 3

• Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Start of enrollment: 2010 Aug 31

  Completed

  Phase 3

• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Start of enrollment: 2010 Nov 11

  Completed

  Phase 3

• Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Start of enrollment: 2011 Jul 22

  Completed

  Phase 3

• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin Start of enrollment: 2011 Dec 01

  Completed

  Phase 3

• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy Start of enrollment: 2011 Dec 01

  Completed

  Phase 3

• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy Start of enrollment: 2012 Aug 01

  Completed

  Phase 3

• Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2012 Sep 01

  Completed

  Phase 3

• Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients Start of enrollment: 2013 Jun 01

  Completed

  Phase 3

• A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Start of enrollment: 2013 Oct 29

  Completed

  Phase 3

• Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data Start of enrollment: 2013 Nov 26

  Completed

  Not Applicable

• Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Start of enrollment: 2014 Nov 11

  Completed

  Phase 3

• Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2014 Oct 01

  Completed

  Phase 3

• Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine Start of enrollment: 2015 Jan 01

  Completed

  Phase 3

• Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion Start of enrollment: 2015 Nov 01

  Completed

  Phase 1

• A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes Start of enrollment: 2017 Jan 17

  Completed

  Phase 3

• Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus Start of enrollment: 2017 Mar 15

  Completed

  Phase 3

• A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes Start of enrollment: 2019 Jun 17

  Active, not recruiting

  Phase 3

• Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System Start of enrollment: 2019 Jul 24

  Completed

  Not Applicable

• Cigarette Pack Inserts for Smoking Cessation Start of enrollment: 2019 Aug 01

  Completed

  Not Applicable

• An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes Start of enrollment: 2020 Jul 19

  Completed

  Not Applicable

• Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® Start of enrollment: 2022 Mar 17

  Active, not recruiting

  Not Applicable

• In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes Start of enrollment: 2022 Feb 25

  Recruiting

  Not Applicable

• Join now to see all